PolyPid Announces Completion of $50 Million Series E-1 Financing

Petah Tikva, Israel, September 4, 2019 — PolyPid Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies, announced today the closing of its $50M Series E-1 preferred shares financing round.